Bemcentinib and Gilteritinib, pharmacological inhibitions of AXL, showed promising as potential COVID-19 therapy (Boytz et al., 2022; Naik et al., 2022; Zdżalik-Bielecka et al., 2022). The gene discussed is AXL; the disease is COVID-19.